采用含卡铂和依托泊苷的大剂量化疗及自体造血干细胞移植治疗复发性和难治性转移性生殖细胞肿瘤。

Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation.

作者信息

Erturk Ismail, Karadurmus Nuri, Kızıloz Halil, Acar Ramazan, Yildiz Birol, Aykan Musa Baris, Esen Ramazan, Buyukturan Galip, Urun Yuksel, Erdem Gokhan, Arpacı Fikret

机构信息

Department of Medical Oncology, Gulhane School of Medicine, University of Health Sciences, Ankara, Turkey.

Department of Urology, Nevsehir Government Hospital, Nevsehir, Turkey.

出版信息

J Oncol Pharm Pract. 2021 Oct;27(7):1657-1664. doi: 10.1177/1078155220964540. Epub 2020 Oct 13.

DOI:10.1177/1078155220964540

PMID:33050802

Abstract

INTRODUCTION AND AIM

To demonstrate the real-life data about patients who underwent AHSCT due to GCT.

METHODS

Between November 2016 and April 2020, 64 patients who received CE as high-dose chemotherapy for AHSCT in the Gulhane Education and Research Hospital were included in the study. Sixty-one patients received one AHSCT with CE chemotherapy regimen. Survival data and clinical characteristics were evaluated retrospectively.

RESULTS

The mean age of the patients were 31.9 ± 9 (min-max:18-55). With a median follow-up of 10.7 ± 8.7 months, the 1-year progression-free survival (PFS) rate was 57.8%, and the 1-year overall survival rate was 77.5%. Median overall survival (OS) and progression-free survival (PFS) times were 21.5 ± 1.8 (95% CI: 14.5-33.4) and 20 ± 2 months, respectively. The response rate was 72%. There were three treatment-related deaths.

CONCLUSION

This sizeable single-centre study shows that patients with relapsed metastatic GCT are curable by CE as high dose chemotherapy plus AHSCT with reliable toxicity even for a single cycle.

摘要

引言与目的

展示因生殖细胞肿瘤（GCT）接受自体造血干细胞移植（AHSCT）患者的真实数据。

方法

2016年11月至2020年4月期间，在古勒汗教育与研究医院接受环磷酰胺（CE）作为AHSCT大剂量化疗的64例患者纳入本研究。61例患者接受了一次采用CE化疗方案的AHSCT。对生存数据和临床特征进行回顾性评估。

结果

患者的平均年龄为31.9±9岁（最小-最大：18-55岁）。中位随访时间为10.7±8.7个月，1年无进展生存率（PFS）为57.8%，1年总生存率为77.5%。中位总生存期（OS）和无进展生存期（PFS）分别为21.5±1.8（95%CI：14.5-33.4）个月和20±2个月。缓解率为72%。有3例与治疗相关的死亡。